BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

714 related articles for article (PubMed ID: 16925290)

  • 21. Laparoscopic gastric bypass: risks vs. benefits up to two years following surgery in super-super obese patients.
    Gould JC; Garren MJ; Boll V; Starling JR
    Surgery; 2006 Oct; 140(4):524-9; discussion 529-31. PubMed ID: 17011899
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Laparoscopic Roux-en-Y gastric bypass in morbidly obese adolescents.
    Stanford A; Glascock JM; Eid GM; Kane T; Ford HR; Ikramuddin S; Schauer P
    J Pediatr Surg; 2003 Mar; 38(3):430-3. PubMed ID: 12632362
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Short-term outcomes for super-super obese (BMI > or =60 kg/m2) patients undergoing weight loss surgery at a high-volume bariatric surgery center: laparoscopic adjustable gastric banding, laparoscopic gastric bypass, and open tubular gastric bypass.
    Stephens DJ; Saunders JK; Belsley S; Trivedi A; Ewing DR; Iannace V; Capella RF; Wasielewski A; Moran S; Schmidt HJ; Ballantyne GH
    Surg Obes Relat Dis; 2008; 4(3):408-15. PubMed ID: 18243060
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preoperative weight gain does not predict failure of weight loss or co-morbidity resolution of laparoscopic Roux-en-Y gastric bypass for morbid obesity.
    Harnisch MC; Portenier DD; Pryor AD; Prince-Petersen R; Grant JP; DeMaria EJ
    Surg Obes Relat Dis; 2008; 4(3):445-50. PubMed ID: 18501309
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Laparoscopic Roux-en-Y gastric bypass surgery for morbid obesity. Experience at the Nacional de Ciencias Médicas y Nutrición Salvador Zubirán].
    Romero-Lbargüengoitia ME; Lerman-Garber I; Herrera-Hernández MF; Pablo-Pantoja J; Sierra-Salazar M; López-Rosales F; Zamora-Barrón M; Vargas-Martínez A; García-García E
    Rev Invest Clin; 2009; 61(3):186-93. PubMed ID: 19736806
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The practice of pancreatic resection after Roux-en-Y gastric bypass.
    Barbour JR; Thomas BN; Morgan KA; Byrne TK; Adams DB
    Am Surg; 2008 Aug; 74(8):729-34. PubMed ID: 18705575
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An update on 73 US obese pediatric patients treated with laparoscopic adjustable gastric banding: comorbidity resolution and compliance data.
    Nadler EP; Youn HA; Ren CJ; Fielding GA
    J Pediatr Surg; 2008 Jan; 43(1):141-6. PubMed ID: 18206472
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improvement of hypothyroidism after laparoscopic Roux-en-Y gastric bypass for morbid obesity.
    Raftopoulos Y; Gagné DJ; Papasavas P; Hayetian F; Maurer J; Bononi P; Caushaj PF
    Obes Surg; 2004 Apr; 14(4):509-13. PubMed ID: 15130228
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of gastrogastric fistulas after divided Roux-en-Y gastric bypass surgery for morbid obesity: analysis of 1,292 consecutive patients and review of literature.
    Carrodeguas L; Szomstein S; Soto F; Whipple O; Simpfendorfer C; Gonzalvo JP; Villares A; Zundel N; Rosenthal R
    Surg Obes Relat Dis; 2005; 1(5):467-74. PubMed ID: 16925272
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Perioperative management of cholelithiasis in patients presenting for laparoscopic Roux-en-Y gastric bypass: have we reached a consensus?
    Patel JA; Patel NA; Piper GL; Smith DE; Malhotra G; Colella JJ
    Am Surg; 2009 Jun; 75(6):470-6; discussion 476. PubMed ID: 19545094
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Initial experience with bariatric surgery in asymptomatic human immunodeficiency virus-infected patients.
    Flancbaum L; Drake V; Colarusso T; Belsley S
    Surg Obes Relat Dis; 2005; 1(2):73-6. PubMed ID: 16925217
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is prophylactic cholecystectomy useful in obese patients undergoing gastric bypass?
    Guadalajara H; Sanz Baro R; Pascual I; Blesa I; Rotundo GS; López JM; Corripio R; Vesperinas G; Sancho LG; Montes JA
    Obes Surg; 2006 Jul; 16(7):883-5. PubMed ID: 16839487
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Laparoscopic management of complications following laparoscopic Roux-en-Y gastric bypass for morbid obesity.
    Papasavas PK; Caushaj PF; McCormick JT; Quinlin RF; Hayetian FD; Maurer J; Kelly JJ; Gagné DJ
    Surg Endosc; 2003 Apr; 17(4):610-4. PubMed ID: 12582772
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Initial outcomes of laparoscopic Roux-en-Y gastric bypass in morbidly obese adolescents.
    Collins J; Mattar S; Qureshi F; Warman J; Ramanathan R; Schauer P; Eid G
    Surg Obes Relat Dis; 2007; 3(2):147-52. PubMed ID: 17324636
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Postoperative CPAP and BiPAP use can be safely omitted after laparoscopic Roux-en-Y gastric bypass.
    Jensen C; Tejirian T; Lewis C; Yadegar J; Dutson E; Mehran A
    Surg Obes Relat Dis; 2008; 4(4):512-4. PubMed ID: 18656832
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Successful endoscopic management of gastrojejunal anastomotic strictures after Roux-en-Y gastric bypass.
    Peifer KJ; Shiels AJ; Azar R; Rivera RE; Eagon JC; Jonnalagadda S
    Gastrointest Endosc; 2007 Aug; 66(2):248-52. PubMed ID: 17451700
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Severity and rate of depression in obese patients after surgical treatment of obesity with Roux-en-Y gastric bypass procedure].
    Kosatka D; Sobów T; Strzelczyk J
    Wiad Lek; 2006; 59(7-8):477-80. PubMed ID: 17209342
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of advanced age on weight loss and health benefits after laparoscopic gastric bypass.
    St Peter SD; Craft RO; Tiede JL; Swain JM
    Arch Surg; 2005 Feb; 140(2):165-8. PubMed ID: 15723998
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anastomotic stenosis after Roux-en-Y gastric bypass: A rational approach to treatment.
    Swartz DE; Gonzalez V; Felix EL
    Surg Obes Relat Dis; 2006; 2(6):632-6; discussion 637. PubMed ID: 17020824
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enoxaparin thromboprophylaxis in gastric bypass patients: extended duration, dose stratification, and antifactor Xa activity.
    Borkgren-Okonek MJ; Hart RW; Pantano JE; Rantis PC; Guske PJ; Kane JM; Gordon N; Sambol NC
    Surg Obes Relat Dis; 2008; 4(5):625-31. PubMed ID: 18261965
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.